LATER TREATMENT AND EARLIER DIAGNOSIS OF DEL(17P) CLL AFTER INTRODUCTION OF TARGETED THERAPIES.

EHA Library, Christian Brieghel, 294611

EXTENDED FOLLOW-UP IN BIRC3-MUTATED RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX PLUS RITUXIMAB: SUBGROUP ANALYSES OF THE MURANO TRIAL

EHA Library, Arnon Philip Kater, 294612

CAUSE OF DEATH IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) STRATIFIED BY THE CLL-INTERNATIONAL PROGNOSTIC INDEX (CLL-IPI)

EHA Library, Yucai Wang, 294613

TUMOR MUTATIONAL LOAD DERIVED FROM RECURRENTLY MUTATED GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PREDICTS TIME-TO-FIRST TREATMENT IN HIGH-COUNT MONOCLONAL B CELL LYMPHOCYTOSIS (HC MBL)

EHA Library, Geffen Kleinstern, 294614

IGHV-ASSOCIATED METHYLATION CHANGES MORE ACCURATELY PREDICT CLINICAL OUTCOMES FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO IGHV MUTATION STATUS

EHA Library, Tomasz K. Wojdacz, 294615

SAFETY OF ACALABRUTINIB MONOTHERAPY IN MATURE B CELL MALIGNANCIES: POOLED ANALYSIS FROM CLINICAL TRIALS

EHA Library, Paolo Ghia, 294616

CHARACTERISTICS AND OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND PARTIAL RESPONSE TO VENETOCLAX-OBINUTUZUMAB

EHA Library, Othman Al-Sawaf, 294617

T-GAMMA/DELTA LARGE GRANULAR LYMPHOCYTE LEUKEMIA IDENTIFIES A SUBSET OF PATIENTS WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF A COLLABORATIVE INTERNATIONAL COHORT OF 130 PATIENTS

EHA Library, Gregorio Barilà, 294618

IMPACT OF VENETOCLAX MONOTHERAPY ON THE QUALITY OF LIFE OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM VENICE II PHASE 3B TRIAL

EHA Library, Tara Cochrane, 294619

INITIAL RESULTS OF A PHASE 1 DOSE ESCALATION STUDY EVALUATION OF MS-553, A NOVEL, SELECTIVE INHIBITOR OF PKC-BETA, IN PATIENTS WITH RELAPSED OR REFRACTORY CLL/SLL

EHA Library, James S. Blachly, 294620

HYPOGAMMAGLOBULINAEMIA AND INFECTIONS IN IBRUTINIB TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PAZIENTS: A PROSPECTIVE STUDY.

EHA Library, Ramona Cassin, 294621

VEMURAFENIB AS TREATMENT OPTION FOR HAIRY CELL LEUKEMIA WITH DEEP NEUTROPENIA AND INFECTIOUS COMPLICATIONS

EHA Library, Lubov Al-Radi, 294622

SAFETY AND ACTIVITY OF THE ONCE DAILY SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR TG-1701 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND LYMPHOMA.

EHA Library, Chan Y. Cheah, 294623

BTK MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA TREATED WITH BTK INHIBITORS: A SINGLE UK INSTITUTION EXPERIENCE

EHA Library, Elisa Santambrogio, 294624

PROGNOSIS ASSESSMENT OF EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA. COMPARISON OF 5 PROGNOSTIC INDEXES

EHA Library, Isabel Gonzalez-Gascon-y-Marin, 294625

EXTRAPOLATING PROGRESSION FREE SURVIVAL CURVES IN CLL USING PERIPHERAL BLOOD MRD MEASUREMENTS FROM VENETOCLAX TRIALS

EHA Library, Dimitra Alexiou, 294626

THE USE OF LONG-TERM ANTITROMBOTIC THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB.

EHA Library, Elena Emelina, 294627

RETROSPECTIVE OBSERVATIONAL STUDY OF THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH IBRUTINIB IN ROUTINE CLINICAL PRACTICE IN SPAIN

EHA Library, Pau Abrisqueta Costa, 294628

EARLY CLINICAL FINDINGS FROM A PHASE 1 A/B DOSE ESCALATION TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF CG-806 IN PATIENTS WITH RELAPSED OR REFRACTORY CLL/SLL OR NON-HODGKIN'S LYMPHOMAS

EHA Library, Rafael Bejar, 294629

PROGNOSTIC BIOMARKER TESTING AND TREATMENT SELECTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PRE- AND POST-APPROVAL OF NOVEL AGENTS

EHA Library, Anthony R. Mato, 294630

LOW - DOSE FCR IN THE FIRST - LINE TREATMENT OF ELDERLY / COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: FINAL RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP.

EHA Library, Lukáš Smolej, 294631

FRAIL PATIENTS WITH CLL CAN BE TREATED WITH NON-INTENSIVE REGIMENS WITHOUT EXCESS HOSPITALIZATIONS – A NATIONWIDE, POPULATION-BASED STUDY

EHA Library, Emelie Curovic Rotbain, 294632

THE PROGNOSTIC SIGNIFICANCE OF DELETION6Q23 DETECTED BY FLUORESCENCE IN SITU HYBRIDIZATION IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Hadiyah Ahmad, 294633

PROGNOSTIC RELEVANCE OF A 3-ITEM SCORING SYSTEM FOR INFECTION RISK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS

EHA Library, Roberta Murru, 294634

TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN THE NEW DRUGS ERA: THE STATE OF ART IN THE ITALIAN LANDSCAPE

EHA Library, Francesca Morelli, 294635

NEUTROPENIA ANALYSIS OF VENETOCLAX MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: POOLED DATA FROM VENICE-I AND -II PHASE 3B TRIALS

EHA Library, Mary Ann Anderson, 294636

EFFECTIVENESS, SAFETY, AND ADHERENCE TO RAMP-UP MONITORING IN ELDERLY CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY UNDER REAL-LIFE CONDITIONS – DATA FROM THE OBSERVATIONAL STUDY VERVE

EHA Library, Ingo Schwaner, 294637

IMPACT OF TREATMENT PATTERN ON SURVIVAL IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA RECEIVING IBRUTINIB OR RITUXIMAB TREATMENT

EHA Library, Shenmiao Yang, 294638

POOR ADHERENCE TO IBRUTINIB IS NOT ASSOCIATED WITH ADVERSE OUTCOME IN RELAPSED REFRACTORY CLL PATIENTS

EHA Library, Eugene NIKITIN, 294639

THE MANAGEMENT AND USE OF HEALTHCARE RESOURCES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) INITIATING VENETOCLAX IN ROUTINE CLINICAL PRACTICE (DEVOTE) ACROSS CANADA: INTERIM ANALYSIS

EHA Library, Versha Banerji, 294640

RISK-ADAPTED BENDAMUSTINE + RITUXIMAB TREATMENT OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A REGIONAL REAL-WORLD REPORT ON 159 CONSECUTIVE SWEDISH PATIENTS

EHA Library, Agnes Mattsson, 294641

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Matthew Davids, 294642

SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS COMPARING THERAPIES FOR TREATMENT-NAÏVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Kavita Sail, 294643

INVESTIGATING THE IMMUNOLOGICAL INTERACTIONS AFTER TKI THERAPY CESSATION IN CML PATIENTS: PREDICTIONS AND RISK ASSESSMENT USING MATHEMATICAL MODELS

EHA Library, Elena Karg, 294645

CHARACTERIZATION OF PHENOTYPIC AND GENOTYPIC MARKERS AS PREDICTORS OF RELAPSE DURING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Alejandro Luna, 294646

SETD2/KDM4A-MEDIATED H3K36ME3 LOSS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN BLAST CRISIS CAN BE THERAPEUTICALLY TARGETED

EHA Library, Manuela Mancini, 294647

DASATINIB INDUCES ENDOTHELIAL TO MESENCHYMAL TRANSITION IN HUMAN VASCULAR ENDOTHELIAL CELLS

EHA Library, Lobna Alkebsi, 294648

THE CRISPR/CAS9 SYSTEM EFFICIENTLY REVERTS THE TUMORIGENIC ABILITY OF BCR/ABL AND RESTORING THE NORMAL HAEMATOPOIESIS IN A MOUSE MODEL OF CHRONIC MYELOGENOUS LEUKAEMIA.

EHA Library, Elena Vuelta Ramos, 294649

SNPS IN ABC GENES CORRELATES WITH MOLECULAR RESPONSE IN CML PATIENTS TREATED WITH NILOTINIB

EHA Library, Federica Loscocco, 294650

DIGITAL PCR FOR THE MEASUREMENT OF BCR- ABL1 IN CML: A NEW DAWN?

EHA Library, Stuart Scott, 294652

DIGITAL DROPLET PCR IS A FAST AND EFFECTIVE TOOL FOR DETECTING T315I MUTATION IN CHRONIC MYELOID LEUKEMIA.

EHA Library, sara galimberti, 294653

NOVEL MULTIPLEX DROPLET DIGITAL PCR ASSAYS TO MONITOR MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA PATIENTS SHOWING ATYPICAL BCR-ABL1 TRANSCRIPTS

EHA Library, Jessica Petiti, 294654

XPERT® BCR-ABL ULTRA: A METHOD OF MONITORING CONVERSION FACTOR STABILITY IN DIAGNOSTIC LABORATORIES

EHA Library, Kathy Dominy, 294655

IMATINIB IS ABLE TO INTERFERE WITH IMMUNE RESPONSE AND INFLAMMATION IN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS FROM THE NANOSTRING APPLICATION.

EHA Library, sara galimberti, 294656

DO NOT WASTE THE DATA: A PIPELINE FOR EVALUATION OF BCR-ABL1 KINASE DOMAIN MUTATION USING INDIVIDUAL THRESHOLDS

EHA Library, Adela Benesova, 294657

DOSE OPTIMIZATION OF SECOND-LINE BOSUTINIB IN ELDERLY CML PATIENTS: FINAL RESULTS OF THE BEST STUDY

EHA Library, Fausto CASTAGNETTI, 294658

THE RATE OF INITIAL BCR-ABL1 DECLINE AFTER COMMENCING TYROSINE KINASE INHIBITOR THERAPY IS PREDICTIVE OF BOTH TREATMENT-FREE REMISSION ELIGIBILITY AND SUBSEQUENT SUSTAINED TREATMENT-FREE REMISSION

EHA Library, Naranie Shanmuganathan, 294659

MOLECULAR RESPONSE BY 24 MONTHS OF NILOTINIB 300 MG BID TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO FAILED TO ACHIEVE DMR WITH IMATINIB: RESULTS FROM THE ENESTPATH STUDY

EHA Library, Delphine Rea, 294661

CONDITIONAL RELATIVE SURVIVAL AMONG ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE TYROSINE KINASE INHIBITOR ERA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 2001-2017

EHA Library, Geneviève Ector, 294662

INTERIM REPORT ON MOLECULAR RESPONSE AND QOL IN PATIENTS OLDER THAN 60 YEARS WITH PH+ CML IN MR3.0/MR4.0 STABLE MOLECULAR RESPONSE INTERMITTENTLY TREATED WITH TKIS (ITALIAN PHASE III OPTKIMA-STUDY)

EHA Library, Michele Malagola, 294663

HLA POLYMORPHISMS PREDICT TREATMENT-FREE REMISSION FOLLOWING TKI DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Hiroshi Ureshino, 294664

LATE MOLECULAR RECURRENCES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA EXPERIENCING TREATMENT FREE REMISSION.

EHA Library, Philippe Rousselot, 294665

IDENTIFICATION OF GENOMIC VARIANTS ASSOCIATED WITH LONG TERM MOLECULAR RESPONSE TO TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Zafar Iqbal, 294666

A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE CHRONIC MYELOID LEUKEMIA (CML): ANALYSIS OF GROWTH AFTER ≥48 TREATMENT CYCLES

EHA Library, Jill Samis, 294667

BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA INTOLERANT TO PRIOR TYROSINE KINASE INHIBITORS: ANALYSES FROM THE BYOND STUDY

EHA Library, Valentin Garcia Gutierrez, 294668

EFFICACY AND SAFETY OF NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSED AFTER DISCONTINUATION OF IMATINIB FOR TREATMENT-FREE REMISSION: RESULTS OF THE FRENCH NILO POST-STIM STUDY

EHA Library, Dulucq Stephanie, 294669

PONATINIB AT A LOWER DOSE IS A GOOD OPTION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS INTOLERANT TO PREVIOUS TKIS

EHA Library, Alessandra Iurlo, 294670

LONG-TERM FOLLOW UP OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH CLONAL CHROMOSOMAL ABERRATIONS IN PHILADELPHIA NEGATIVE CELLS TREATED WITH TYROSINE KINASE INHIBITORS

EHA Library, Christos VARELAS, 294671

FAVORABLE OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CO-EXPRESSING E13A2 AND E14A2 TRANSCRIPT TREATED FRONTLINE WITH NILOTINIB

EHA Library, Maria Pina Simula, 294672

IS BCR-ABL1 TRANSCRIPT A RELIABLE MARKER AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT)? LONG-TERM FOLLOW-UP OF CML ALLOTRANSPLANTED PATIENTS WITH BCR/ABL1 FLUCTUATIONS

EHA Library, Antonella Antonella Bruzzese, 294673

DASATINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB THERAPY: 3-YEAR EXTENDED FOLLOW-UP (FU) FROM DASCERN

EHA Library, Jorge CORTES, 294674

SECOND GENERATION TYROSINE KINASE INHIBITORS IN THE FIRST-LINE CAN REDUCE TIME TO TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Oleg Shukhov, 294675

TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY.

EHA Library, Camille C.B. Kockerols, 294676

RETROSPECTIVE INDEPENDENT REVIEW OF ARTERIAL OCCLUSIVE EVENTS (AOES) IN THE PHASE 2 PACE TRIAL OF PONATINIB IN PHILADELPHIA CHROMOSOME POSITIVE (PH+) LEUKEMIA

EHA Library, James Januzzi, 294677

IMATINIB CORRECTS IMMUNE EXHAUSTION OF CYTOTOXIC T-LYMPHOCYTES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Fen Saj, 294678

DETERMINANTS OF FIRST-LINE THERAPY CHOICE IN CHRONIC PHASE CML: A REAL-LIFE SURVEY IN ITALY

EHA Library, Mario Tiribelli, 294679

NEXT GENERATION SEQUENCING IDENTIFIES COMMON MUTATIONAL SIGNATURES IN NOVEL GENES REPRESENTING DIFFERENT BIOLOGICAL PATHWAYS ASSOCIATED WITH ACUTE TRANSFORMATION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Zafar Iqbal, 294680

INDUCTION AND MAINTENANCE FOR CHRONIC MYELOID LEUKEMIA -CHRONIC PHASE: A NOVEL TREATMENT STRATEGY

EHA Library, Aditi Jain, 294681

A CROSS TALK BETWEEN TREATMENT FREE REMISSION AND CML POPULATION AGING

EHA Library, Marc Delord, 294682

THE REAL–LIFE STUDY EVALUATING THE EFFICACY AND SAFETY OF PONATINIB 'TOPASE' REVEALS INDUCTION OF DEEP MOLECULAR RESPONSES IN A COHORT OF 75 TKI-RESISTANT OR INTOLERANT PATIENTS WITH CML

EHA Library, Turhan Ali, 294683

BOSUTINIB FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AFTER IMATINIB FAILURE: ≥8-YEAR UPDATE OF A PHASE 1/2 STUDY

EHA Library, Jorge CORTES, 294684

LONG-TERM OUTCOMES OF TYROSINE KINASE INHIBITOR IN THIRD-LINE THERAPY OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Tamara Chitanava, 294685

CLINICAL IMPACTS OF GERMLINE AND SOMATIC DDX41 MUTATIONS ON MYELOID NEOPLASMS.

EHA Library, Hideki Makishima, 294686

MODULATION OF THE IL-6/STAT3 SIGNALING AXIS IN CD4+ T CELLS REPRESENTS A IMMUNE-MEDIATED MECHANISM OF ACTION OF AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Ioannis Kotsianidis, 294687

LOSS OF INTRON RETENTION INDUCES LOSS OF R-LOOPS AND REPLICATION STRESS IN SF3B1-MUTATED ERYTHROBLASTS

EHA Library, Carine Lefèvre, 294688

IN VITRO AND IN VIVO PRECLINICAL MODELS FOR TESTING NEW THERAPIES FOR AZACITIDINE-RESISTANT MDS/AML.

EHA Library, Tomas Stopka, 294690

KINETIC PROFILING IDENTIFIES AGE- AND MDS- RELATED CHANGES IN HEMATOPOIETIC STEM AND PROGENITOR CELL DYNAMICS

EHA Library, Michele Buck, 294691

DISTINCT ETHNIC, CLINICAL, AND GENETIC CHARACTERISTICS OF DER(1;7) IN MYELODYSPLASTIC SYNDROMES.

EHA Library, Rurika Okuda, 294692

THE IMPACT OF MICROMEGAKARYOCYTES ON THE MYELODYSPLASTIC SYNDROMES PROGNOSIS

EHA Library, SILVIA SAUMELL, 294693

EFFECT OF LUSPATERCEPT (RAP-536) ON MDS PDX-MURINE MODELS WITH OR WITHOUT SF3B1 MUTATION

EHA Library, Mathieu Meunier, 294694

EVALUATING PATHOGENICITY OF RUNX1 VARIANTS OF UNCERTAIN SIGNIFICANCE BY APPLYING FUNCTIONAL ASSAYS ADDRESSING DIFFERENT MOLECULAR ASPECTS OF THE RUNX1:CBFΒ TRANSCRIPTION FACTOR COMPLEX

EHA Library, Tim Ripperger, 294695

PROMOTER CHROMATIN STATE TRANSITIONS AND TRANSCRIPTIONAL ACTIVITY IN ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Moritz Binder, 294696

LOW IGF1 SIGNALING IN MYELODYSPLASTIC CD34+ HSC IS ASSOCIATED WITH A LEUKEMIC STEM CELL SIGNATURE, REDUCED PROLIFERATIVE ACTIVITY AND POOR PROGNOSIS

EHA Library, Thomas Luft, 294697

INHIBITION OF GLYCOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR NEW APPROACH FOR THE TARGETED THERAPY OF MDS

EHA Library, Seiichi Okabe, 294698

KER-050, A NOVEL MODIFIED ACTRIIA LIGAND TRAP, INCREASES RED BLOOD CELL PRODUCTION IN CYNOMOLGUS MONKEYS

EHA Library, KEITH BABBS, 294699

IMPACT OF RAS-PATHWAY ACTIVATION ON PHENOTYPE AND OUTCOME IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA AND A TET2/SRSF2 COMUTATION

EHA Library, Klaus Geissler, 294700

UPREGULATED HIF-1Α EXPRESSION IN HIGH RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA PATIENTS IS ASSOCIATED WITH BETTER RESPONSE TO AZACITIDINE - DATA FROM THE HELLENIC MDS STUDY GROUP

EHA Library, Vasiliki Pappa, 294701

TP53 STATUS AND OUTCOME IN MYELODYSPLASTIC SYNDROMES WITH COMPLEX ABERRANT KARYOTYPES

EHA Library, Detlef Haase, 294702

KER-050, A NOVEL INHIBITOR OF TGFΒ SUPERFAMILY SIGNALING, INDUCES RED BLOOD CELL PRODUCTION AND IS A POTENTIAL CANDIDATE FOR THE TREATMENT OF INEFFECTIVE HEMATOPOIESIS

EHA Library, Marina Feigenson, 294703

SEVERE ERYTHROID LINEAGE FAILURE DISCRIMINATES RESPONSE AND PROGNOSIS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Huijun Huang, 294704

ATYPICAL DELETIONS OF THE LONG ARM OF CHROMOSOME 5 WITH RETAINED COMMONLY DELETED REGIONS (CDR) IN MDS

EHA Library, Zuzana Zemanova, 294705

BIOENERGETIC ALTERATIONS AS DEFINING FEATURES OF LOW VERSUS HIGH RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Aikaterini Poulaki, 294706

CD3+CD56+ CELLS (TR3-56) AND IMMUNE TOLERANCE CONTROL IN THE BONE MARROW (BM) OF MYELODYSPLASTYC SYNDROME (MDS) INDIVIDUALS.

EHA Library, Stefania Leone, 294707

COMPARISON OF CLINICAL, GENETIC CHARACTERISTICS AND PROGNOSIS OF CMML WITH OR WITHOUT RING SIDEROBLASTS AND MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS WITH OR WITHOUT MONOCYTOSIS

EHA Library, Blanca Xicoy, 294708

DEFERASIROX-DEPENDENT IRON CHELATION AFFECTS MITOCHONDRIAL DYNAMICS AND STRUCTURE AND RESTORES TP53 FAMILY MEMBERS SIGNALING

EHA Library, Cristina Panuzzo, 294709

DNA REPAIR MECHANISMS IN MYELODYSPLASTIC SYNDROMES (MDS): DIFFERENTIAL GENE EXPRESSION IN MDS SUBTYPES

EHA Library, Stamatina Roussou, 294710

MOLECULAR CHARACTERISTICS THAT PREDICT RESPONSE TO AZACITIDINE THERAPY

EHA Library, Yasuhito Nannya, 294711

ASSESSING THE DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Igor Stojkov, 294713

MOLECULAR AND CLINICAL FEATURES OF MYELOID NEOPLASMS WITH SOMATIC DDX41 MUTATIONS

EHA Library, Zhijian Xiao, 294714

CLINICAL BENEFIT OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) AND HIGH TRANSFUSION BURDEN (HTB) IN THE PHASE 3 MEDALIST STUDY

EHA Library, Amer Zeidan, 294715